Emil D. Kakkis

2018

In 2018, Emil D. Kakkis earned a total compensation of $4.8M as President and Chief Executive Officer at Ultragenyx Pharmaceutical, a 28% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$428,400
Option Awards$2,753,513
Salary$679,952
Stock Awards$944,385
Other$39,377
Total$4,845,627

Kakkis received $2.8M in option awards, accounting for 57% of the total pay in 2018.

Kakkis also received $428.4K in non-equity incentive plan, $680K in salary, $944.4K in stock awards and $39.4K in other compensation.

Rankings

In 2018, Emil D. Kakkis' compensation ranked 2,104th out of 14,244 executives tracked by ExecPay. In other words, Kakkis earned more than 85.2% of executives.

ClassificationRankingPercentile
All
2,104
out of 14,244
85th
Division
Manufacturing
763
out of 5,759
87th
Major group
Chemicals And Allied Products
255
out of 2,122
88th
Industry group
Drugs
203
out of 1,811
89th
Industry
Pharmaceutical Preparations
157
out of 1,385
89th
Source: SEC filing on April 22, 2019.

Kakkis' colleagues

We found six more compensation records of executives who worked with Emil D. Kakkis at Ultragenyx Pharmaceutical in 2018.

2018

Wladimir Hogenhuis

Ultragenyx Pharmaceutical

Chief Operating Officer

2018

Camille Bedrosian

Ultragenyx Pharmaceutical

Chief Medical Officer

2018

Shalini Sharp

Ultragenyx Pharmaceutical

Chief Financial Officer

2018

Karah Parschauer

Ultragenyx Pharmaceutical

General Counsel

2018

Thomas Kassberg

Ultragenyx Pharmaceutical

Chief Business Officer and Executive Vice President

2018

John Pinion

Ultragenyx Pharmaceutical

Chief Quality Officer and Executive Vice President, Translational Sciences

News

In-depth

You may also like